The Menin Inhibitor Revumenib in KMT2A-Rearranged or NPM1-Mutant Leukemia

Researchers described the results of the first-in-human Phase I clinical trial investigating revumenib, a potent and selective oral inhibitor of the menin–KMT2A interaction, in patients with relapsed or refractory acute leukemia.